Total Payments
$219,617
2024 Payments
$88,034
Companies
22
Transactions
169
Medicare Patients
1,377
Medicare Billing
$204,723
Payment Breakdown by Category
Consulting$163,734 (74.6%)
Travel$29,107 (13.3%)
Other$21,260 (9.7%)
Food & Beverage$4,306 (2.0%)
Research$1,139 (0.5%)
Education$71.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $163,734 | 40 | 74.6% |
| Travel and Lodging | $29,107 | 45 | 13.3% |
| Honoraria | $13,700 | 4 | 6.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,560 | 1 | 3.4% |
| Food and Beverage | $4,306 | 70 | 2.0% |
| Unspecified | $1,139 | 8 | 0.5% |
| Education | $71.99 | 1 | 0.0% |
Payments by Type
General
$218,478
161 transactions
Research
$1,139
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $101,939 | 58 | $0 (2024) |
| Kite Pharma, Inc. | $44,473 | 38 | $0 (2024) |
| ADC Therapeutics America, Inc. | $38,345 | 31 | $0 (2024) |
| PFIZER INC. | $10,223 | 4 | $0 (2020) |
| Janssen Biotech, Inc. | $5,555 | 6 | $0 (2022) |
| Spectrum Pharmaceuticals Inc. | $3,676 | 7 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $2,865 | 1 | $0 (2024) |
| BeiGene USA, Inc. | $2,625 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $2,135 | 1 | $0 (2024) |
| TG THERAPEUTICS, INC. | $2,025 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,034 | 56 | Gilead Sciences, Inc. ($66,424) |
| 2023 | $54,783 | 35 | Gilead Sciences, Inc. ($24,169) |
| 2022 | $22,460 | 17 | ADC Therapeutics America, Inc. ($11,193) |
| 2021 | $12,075 | 8 | Janssen Biotech, Inc. ($3,788) |
| 2020 | $10,235 | 6 | PFIZER INC. ($7,655) |
| 2019 | $18,012 | 25 | Kite Pharma, Inc. ($16,874) |
| 2018 | $13,949 | 21 | Gilead Sciences, Inc. ($5,897) |
| 2017 | $67.95 | 1 | PFIZER INC. ($67.95) |
All Payment Transactions
169 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $54.15 | General |
| 12/08/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $46.89 | General |
| Category: CELLT | ||||||
| 11/06/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $85.41 | General |
| 10/04/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $276.64 | General |
| 10/04/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $143.89 | General |
| 10/04/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $64.00 | General |
| 10/04/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $49.00 | General |
| 10/04/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $39.00 | General |
| 09/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 09/06/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $248.04 | General |
| 09/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $115.00 | General |
| 09/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| 09/05/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $139.92 | General |
| Category: Monoclonal Antibody | ||||||
| 08/27/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $953.32 | General |
| 07/17/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $15,770.00 | General |
| Category: CELLT | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $107.26 | General |
| Category: CELLT | ||||||
| 06/17/2024 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $2,570.00 | General |
| Category: CELLT | ||||||
| 06/14/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $39.50 | General |
| 06/05/2024 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $4,900.00 | General |
| 06/05/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $237.18 | General |
| 05/31/2024 | Kite Pharma, Inc. | Tecartus (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 05/18/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $183.99 | General |
| 05/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $94.24 | General |
| 05/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL | Gilead Sciences, Inc. | $1,139 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 299 | 538 | $197,242 | $40,710 |
| 2022 | 8 | 380 | 723 | $232,796 | $55,241 |
| 2021 | 8 | 384 | 761 | $253,568 | $64,664 |
| 2020 | 10 | 314 | 646 | $189,600 | $44,108 |
Total Patients
1,377
Total Services
2,668
Medicare Billing
$204,723
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 108 | 189 | $60,102 | $12,442 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 74 | 105 | $45,045 | $10,002 | 22.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 123 | $37,269 | $7,425 | 19.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 47 | $20,492 | $4,260 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $11,124 | $2,441 | 21.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 22 | $12,606 | $2,100 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 18 | $5,724 | $1,061 | 18.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 16 | 16 | $4,880 | $980.64 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 151 | 279 | $88,722 | $19,574 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 94 | 153 | $65,826 | $14,664 | 22.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 126 | $34,776 | $9,625 | 27.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 90 | $15,210 | $4,764 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $17,922 | $3,799 | 21.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $3,852 | $1,125 | 29.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 18 | 18 | $3,096 | $923.71 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 16 | $3,392 | $765.63 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 118 | 228 | $97,812 | $24,171 | 24.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 98 | 169 | $53,742 | $11,485 | 21.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 144 | $39,744 | $10,609 | 26.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 113 | $19,097 | $6,064 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 29 | 32 | $15,104 | $5,029 | 33.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $17,922 | $4,126 | 23.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 27 | 31 | $5,332 | $1,594 | 29.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 15 | $4,815 | $1,587 | 33.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 116 | 275 | $83,437 | $14,952 | 17.9% |
About Olalekan Oluwole, MD, MPH
Olalekan Oluwole, MD, MPH is a Hospitalist healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2008. The National Provider Identifier (NPI) number assigned to this provider is 1699947655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Olalekan Oluwole, MD, MPH has received a total of $219,617 in payments from pharmaceutical and medical device companies, with $88,034 received in 2024. These payments were reported across 169 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($163,734).
As a Medicare-enrolled provider, Oluwole has provided services to 1,377 Medicare beneficiaries, totaling 2,668 services with total Medicare billing of $204,723. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Nashville, TN
- Active Since 03/31/2008
- Last Updated 03/28/2022
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1699947655
Products in Payments
- Yescarta (Drug) $59,889
- Tecartus (Drug) $17,332
- BESPONSA (Biological) $7,560
- Folotyn (Drug) $3,320
- BRUKINSA (Drug) $2,625
- UKONIQ (Drug) $2,025
- CARVYKTI (Drug) $1,768
- Non-Covered $1,753
- TAZVERIK (Drug) $1,500
- IMBRUVICA (Drug) $505.00
- Poteligeo (Drug) $139.92
- GAMIFANT (Drug) $79.99
- REZUROCK (Drug) $71.12
- BESPONSA (Drug) $67.95
- Pomalyst (Drug) $39.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in Nashville
Andrew Zurick, M.d, M.D
Hospitalist — Payments: $171,446
Hospitalist $171,446
Dr. Sonya Reid, Md, MD
Hospitalist — Payments: $99,563
Hospitalist $99,563
Christopher Hoffman, Md, MD
Hospitalist — Payments: $43,485
Hospitalist $43,485
Ravi Mishra, Md, MD
Hospitalist — Payments: $6,123
Hospitalist $6,123
Courtney Havill, Fnp-C, FNP-C
Hospitalist — Payments: $3,934
Hospitalist $3,934
Philip Kuo, Md, MD
Hospitalist — Payments: $3,825
Hospitalist $3,825